The research, published in BMC Endocrine Disorders, followed 10,487 adults who underwent routine health check-ups at the hospital in 2018 and then returned for follow-up assessment in 2023. The investigators deliberately excluded anyone who already had hyperuricemia or gout at the start, ensuring that the analysis captured genuinely new cases rather than pre-existing disease. Over the five-year window, 1,455 participants, or 13.8 percent of the cohort, developed hyperuricemia. The gender split was striking: 17.6 percent of men crossed the diagnostic threshold compared with only 9.8 percent of women, nearly doubling the male burden and reinforcing a pattern that clinicians have observed for decades.

At the heart of the study lies metabolic syndrome, or MetS, a cluster of interrelated abnormalities that includes abdominal obesity, elevated triglycerides, low levels of high-density lipoprotein cholesterol, high blood pressure, and high fasting glucose. A person is typically classified as having MetS when three or more of these components are present. Because each component is itself a known cardiovascular risk factor, researchers have long suspected that the syndrome as a whole might accelerate the accumulation of uric acid in the blood. The Nanjing team set out to test this hypothesis quantitatively, and to determine whether the strength of the association differed between the sexes.

The methodological approach combined classical epidemiology with modern statistical learning. The researchers used multivariable logistic regression, stratified by gender, to estimate the odds of developing hyperuricemia associated with MetS and each of its individual components, adjusting for a battery of potential confounders. They also constructed a composite MetS score reflecting the number of metabolic abnormalities each participant carried. To sharpen the predictive picture, they applied least absolute shrinkage and selection operator regression, known as LASSO, a technique that penalizes model complexity and automatically winnows out weak predictors. The surviving variables were then assembled into a nomogram, a graphical calculation tool that clinicians can use to estimate an individual patient’s five-year risk of hyperuricemia from a handful of routine measurements.

The headline finding was unambiguous: metabolic syndrome significantly increased the risk of new-onset hyperuricemia in both sexes. After adjustment for confounding factors, men with MetS had a 22 percent higher odds of developing the condition, with an odds ratio of 1.22 and a 95 percent confidence interval of 1.02 to 1.45. Women with MetS fared considerably worse in relative terms, with an odds ratio of 1.42 and a confidence interval of 1.04 to 1.95, translating to a 42 percent elevation in risk. Both results reached statistical significance, but the pattern suggests that although men develop hyperuricemia more often in absolute terms, the metabolic syndrome exerts a proportionally stronger push toward the disease in women.

When the investigators dissected the syndrome into its individual components, a clear hierarchy emerged. Three factors stood out as significant drivers of rising uric acid: abdominal obesity, hypertriglyceridemia, and low high-density lipoprotein cholesterol. Notably, the effects of all three were stronger in women than in men, sharpening the gender contrast that runs through the entire study. In contrast, two components that many clinicians might intuitively expect to matter, hyperglycemia and high blood pressure, showed no significant association with the development of hyperuricemia in either sex. This dissociation is scientifically intriguing. It suggests that the pathways linking insulin resistance and fat metabolism to uric acid handling are not simply a generalized consequence of metabolic dysfunction, but instead run through specific channels tied to visceral adiposity and lipid derangement.

The biology behind these associations is plausible and increasingly well understood. Abdominal obesity reflects an accumulation of visceral fat, an metabolically active tissue that promotes the breakdown of adenosine triphosphate and increases the production of purines, the molecular precursors of uric acid. Visceral fat also generates inflammatory signals that can impair renal excretion of urate. Elevated triglycerides and depressed HDL cholesterol are hallmarks of impaired lipid processing, and insulin resistance, which threads through these abnormalities, is known to reduce the renal excretion of uric acid by altering sodium and urate transport in the proximal tubule. The fact that blood pressure and glucose failed to reach significance in this cohort does not mean they are irrelevant to metabolic health; it means that, within this population and over this time frame, they did not independently predict the onset of hyperuricemia once the stronger lipid and adiposity signals were accounted for.

The MetS score analysis added a dose-response dimension to the findings. A score of two or higher markedly increased the risk of hyperuricemia regardless of gender, indicating that even subthreshold combinations of metabolic abnormalities begin to exert measurable pressure on uric acid homeostasis. This graded relationship carries practical implications: patients who do not yet meet the formal criteria for metabolic syndrome but who carry two components, such as a widening waistline and creeping triglycerides, may already be on a trajectory toward clinically significant hyperuricemia and could benefit from earlier intervention.

The LASSO regression distilled the predictive signal down to four key variables: gender, waist circumference, triglycerides, and baseline serum uric acid. The resulting nomogram achieved an area under the curve, or AUC, of 0.774, a level of discrimination that is respectable for a simple clinical tool built from routine check-up data. An AUC of 0.774 means the model correctly ranks a randomly selected future hyperuricemia patient above a randomly selected non-patient roughly 77 percent of the time. That is not perfect prediction, but it is sufficient to flag high-risk individuals for closer monitoring, lifestyle counseling, or earlier urate-lowering therapy decisions. The prominence of baseline serum uric acid among the predictors is unsurprising, since people starting closer to the diagnostic threshold have less distance to travel, but the independent contributions of waist circumference and triglycerides underscore that modifiable metabolic factors carry genuine prognostic weight.

The gender-specific findings deserve particular attention as hyperuricemia and gout rates continue to climb worldwide alongside expanding waistlines. In premenopausal women, estrogen is thought to promote renal urate excretion, which helps explain the lower baseline incidence in females. The stronger relative effect of metabolic syndrome in women observed here hints that when metabolic dysfunction does take hold in female patients, it may erode this protective margin more aggressively than in men, or that the diagnostic thresholds and hormonal context interact in ways that amplify risk. For clinicians, the message is that a one-size-fits-all risk assessment may be inadequate: a woman with abdominal obesity, high triglycerides, and low HDL cholesterol warrants vigilance for hyperuricemia that her blood pressure and glucose numbers alone would not reveal. For the public, the study distills into a familiar but newly urgent prescription: the fat around the midsection and the fats circulating in the blood are the metabolic levers most tightly connected to the crystallization risk of gout, and keeping them in check over the long term may spare millions of people from a disease that literally sharpens its own needles inside the joints.

Subject of Research: Gender differences in how metabolic syndrome components influence the five-year risk of developing hyperuricemia

Article Title: Gender differences in the association between metabolic syndrome components and 5-year risk of hyperuricemia: a retrospective cohort study

Article References: Cui, W., Gao, L., Li, N., Zhou, W., & Hu, Y. (2026). Gender differences in the association between metabolic syndrome components and 5-year risk of hyperuricemia: a retrospective cohort study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02611-5

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02611-5

Keywords: hyperuricemia, metabolic syndrome, gout, uric acid, abdominal obesity, triglycerides, HDL cholesterol, gender differences, cohort study, nomogram, cardiovascular risk, insulin resistance